Skip to content
10-Q

Quarterly Report

Arcadia Biosciences, Inc. RKDA

0001193125-26-223990

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 2.06M sh
Shares Diluted Q1 2026 · Mar 31, 2026 2.08M sh
Shares Diluted Q1 2026 · Mar 31, 2025 1.37M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$1.1M
Operating Cash Flow Q1 2026 · Dec 31, 2025 −$4.7M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.59M
Short Term Investments Q1 2026 · Mar 31, 2026 $2.77M
Short Term Investments Q1 2026 · Dec 31, 2025 $4.3M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $954K
Cash And Equivalents Q1 2026 · Dec 31, 2025 $259K
Current Liabilities Q1 2026 · Mar 31, 2026 $1.37M
Current Liabilities Q1 2026 · Dec 31, 2025 $2.06M
Total Liabilities Q1 2026 · Mar 31, 2026 $2.44M
Total Liabilities Q1 2026 · Dec 31, 2025 $2.41M
Current Assets Q1 2026 · Mar 31, 2026 $5.17M
Current Assets Q1 2026 · Dec 31, 2025 $6.36M
Total Assets Q1 2026 · Mar 31, 2026 $5.32M
Total Assets Q1 2026 · Dec 31, 2025 $6.55M
Eps Diluted Q1 2026 · Mar 31, 2026 −$2.11
Eps Diluted Q1 2026 · Mar 31, 2025 $1.90
Eps Basic Q1 2026 · Mar 31, 2026 −$2.11
Eps Basic Q1 2026 · Mar 31, 2025 $1.90
Sga Expense Q1 2026 · Mar 31, 2026 $1.18M
Sga Expense Q1 2026 · Mar 31, 2025 $1.74M
Net Income Q1 2026 · Mar 31, 2026 −$4.39M
Net Income Q1 2026 · Mar 31, 2025 $2.6M
Operating Income Q1 2026 · Mar 31, 2026 −$779K
Operating Income Q1 2026 · Mar 31, 2025 $530K
Cost Of Revenue Q1 2026 · Mar 31, 2026 $700K
Cost Of Revenue Q1 2026 · Mar 31, 2025 $682K
Revenue Q1 2026 · Mar 31, 2026 $1.1M
Revenue Q1 2026 · Mar 31, 2025 $1.2M